(lp0
S'Exclusive: Impax Laboratories taps Morgan Stanley for strategic review - sources Reuters - Mar 7, 2017 Generic drugmaker Impax Laboratories Inc  has asked investment bank Morgan Stanley  to help it conduct a strategic review, as it tries to cope with a tougher drug pricing environment, people familiar with the matter said.Impax Laboratories Inc.  Moves Higher on Volume Spike for March 06 - Equities.com'
p1
aS'Impax to Present at Upcoming Investor Conferences PR Newswire  - Feb 27, 2017 Impax Laboratories, Inc.  is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous ...Impax Laboratories, Inc.  Scheduled to Post Earnings on Wednesday - Sports PerspectivesImpax Laboratories, Inc.  Receives An Update From Brokers - The De Soto Edge'
p2
aS'Earnings Reaction History: Impax Laboratories, Inc., 50.0% Follow-Through ... Nasdaq - Mar 1, 2017 Impax Laboratories, Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session.'
p3
aS'Impax Laboratories, Inc.  Files An 8-K Results of Operations and ... Market Exclusive - Mar 1, 2017 Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , as well as the development and marketing of branded products.Impax Laboratories Inc.  Has Dropped To A New Low After Q4 Report - NasdaqImpax Laboratories Inc.  Plunges 14.44% on March 03 - Equities.com'
p4
aS'Impax Laboratories Inc.  Settles Into New 52-Week Low on March 07 Session Equities.com - Mar 7, 2017 Shares of Impax Laboratories Inc.  sank into a new 52-week low yesterday, and could be a company to watch at the open.'
p5
aS'Impax Laboratories  is Oversold: Can It Recover? March 02, 2017 Zacks.com - Mar 2, 2017 Impax Laboratories, Inc.  has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.'
p6
aS"Sell-Side Analyst's Predictions: Impax Laboratories , Prospect Capital ... The USA Commerce - Mar 17, 2017 Presently Impax Laboratories, Inc.  stock have an ABR of 2.78. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.Featured Stock to Focus: Impax Laboratories Inc.  - FactsReporterZacks Rank on Impax Laboratories, Inc.  based on Estimated Earnings - Highland Mirror"
p7
aS'Renaissance Technologies LLC Increases Position in Impax Laboratories Inc  The Cerbat Gem - Mar 16, 2017 Impax Laboratories logo Renaissance Technologies LLC raised its position in shares of Impax Laboratories Inc  by 515.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC.The Impax Laboratories Inc  Downgraded by Susquehanna Bancshares Inc to ... - Petro Global News 24Under Focus Analysis: Impax Laboratories Inc.  - The Oracle Examiner'
p8
aS'Impax Laboratories Inc  Lowered to Neutral at Susquehanna Bancshares Inc BNB Daily  - Mar 14, 2017 Impax Laboratories Inc logo Susquehanna Bancshares Inc cut shares of Impax Laboratories Inc  from a positive rating to a neutral rating in a research note released on Wednesday morning.Susquehanna Bancshares Inc Lowers Impax Laboratories Inc  to Neutral - Chaffey Breeze112 institutional investors are raising stakes in Impax Laboratories, Inc ... - Post Analyst'
p9
aS'Revenue Approximations Analysis: Tenet Healthcare Corp. , Impax ... StockNewsJournal - Mar 8, 2017 Impax Laboratories, Inc. , at its latest closing price of $9.10, it has a price-to-book ratio of 0.99, compared to an industry average at 4.15.'
p10
a.